Sagent Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 36 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Sagent Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sagent-pharmaceuticals-inc

Overview

Sagent Pharmaceuticals, Inc. is a leading developer, manufacturer, and marketer of pharmaceutical products with a focus on injectable drugs. As a subsidiary of Nichi-Iko Pharmaceutical Co., Ltd., Sagent emphasizes quality and innovation in producing essential medicines for healthcare providers.

Therapeutic areas

Injectable DrugsAnestheticsAntibioticsCardiovascularOncology

FDA compliance signals

36 FDA enforcement records linked to this company.

  • recall — Class III2026-05-27

    Failed Impurities/Degradation Specifications

  • recall — Class I2024-06-19

    Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

  • recall — Class I2024-06-19

    Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

  • recall — Class II2024-05-22

    Presence of Particulate Matter: Potential for black particulates in the drug product.

  • recall — Class II2023-08-02

    Lack of Assurance of Sterility

  • recall — Class II2023-08-02

    Lack of Assurance of Sterility

  • recall — Class II2023-08-02

    Lack of Assurance of Sterility

  • recall — Class II2023-05-31

    Lack of Assurance of Sterility

  • recall — Class II2023-05-31

    Lack of Assurance of Sterility

  • recall — Class II2023-05-31

    Lack of Assurance of Sterility

  • recall — Class II2023-03-15

    Labeling: Not elsewhere classified

  • recall — Class II2021-03-24

    Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may result in a non-sterile product.

  • 4832019-12-18

    Contract drug products--lack of responsibility

  • 4832019-12-18

    Failure to meet specifications

  • 4832019-12-18

    SOPs not followed / documented

  • 4832019-12-18

    Authority lacking to review records, investigate errors

  • 4832019-12-18

    Contamination, chemical or physical change, deterioration

  • 4832019-12-18

    Inadequate number of personnel

  • 4832019-12-18

    Procedures not in writing, fully followed

  • recall — Class II2019-05-15

    Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.

  • 4832018-09-24

    Summary

  • 4832018-09-24

    Submission of report follow-up

  • 4832018-09-24

    Failure to develop written procedures

  • 4832018-09-24

    Late submission of 15-day report

  • recall — Class II2018-03-21

    Failed Impurities/Degradation Specifications: High out of specification results for an impurity.

  • recall — Class II2018-03-21

    Failed Impurities/Degradation Specifications: High out of specification results for an impurity.

  • recall — Class II2018-03-21

    Failed Impurities/Degradation Specifications: High out of specification results for an impurity.

  • recall — Class II2016-08-03

    Presence of Particulate Matter; The firm received two product complaints for small, dark particulate matter identified in solution post reconstitution.

  • recall — Class II2016-03-30

    Cross contamination with other products: metronidazole

  • recall — Class II2015-03-11

    Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.

  • recall — Class II2015-03-11

    Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.

  • recall — Class II2014-10-22

    Incorrect or Missing Lot and/or Exp Date: Ketorolac Tromethamine Injection, is being recalled as a result of labeling the product with the incorrect expiration date.

  • recall — Class II2014-10-08

    Lack of Assurance of Sterility; leaking of premix bags

  • recall — Class II2013-06-26

    CGMP Deviations: product was not manufactured under current good manufacturing practices which contributed to Failed Impurities/Degradation Specifications as a high out of specification impurity result was detected during routine quality testing of stability samples.

  • 4832012-05-11

    Failure to report non-alert ADEs

  • 4832012-05-11

    Failure to develop written procedures

For suppliers

Is this Sagent Pharmaceuticals, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.